CNS Pharmaceuticals Inc
CNSP5.490USD
+0.080+1.48%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.15MMarktkapitalisierung
0.01KGV TTM
mehr Informationen über CNS Pharmaceuticals Inc Unternehmen
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc Informationen
BörsenkürzelCNSP
Name des UnternehmensCNS Pharmaceuticals Inc
IPO-datumNov 08, 2019
CEOClimaco (John Michael)
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
Addresse2100 West Loop S Ste 900
StadtHOUSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77027-3522
Telefon18009469185
Websitehttps://cnspharma.com/
BörsenkürzelCNSP
IPO-datumNov 08, 2019
CEOClimaco (John Michael)
Führungskräfte von CNS Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-3.00%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+1.00%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-1.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Bettina M. Cockroft, M.D.
Dr. Bettina M. Cockroft, M.D.
Independent Director
Independent Director
--
-1.00%
Ms. Amy Mahery
Ms. Amy Mahery
Independent Director
Independent Director
--
-1.00%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-3.00%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+1.00%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-1.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
UBS Financial Services, Inc.
0.03%
Andere
92.29%
Aktionäre
Aktionäre
Anteil
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
UBS Financial Services, Inc.
0.03%
Andere
92.29%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.19%
Investment Advisor
2.30%
Corporation
0.15%
Bank and Trust
0.07%
Andere
92.28%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
34
57.74K
7.40%
+32.22K
2025Q3
34
25.52K
7.99%
-17.21K
2025Q2
30
42.73K
1.82%
+37.38K
2025Q1
30
5.15K
1.78%
+786.00
2024Q4
28
5.89K
1.26%
+3.16K
2024Q3
24
2.73K
0.48%
+2.49K
2024Q2
21
240.00
1.54%
+206.00
2024Q1
23
34.00
3.95%
+20.00
2023Q4
20
11.00
4.00%
+6.00
2023Q3
22
5.00
7.14%
--
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
DRW Securities, LLC
14.05K
2.27%
+14.05K
--
Sep 30, 2025
Cortice Biosciences, Inc.
956.00
0.17%
+956.00
--
Jul 30, 2024
UBS Switzerland AG
416.00
0.07%
+416.00
--
Sep 30, 2025
UBS Financial Services, Inc.
2.67K
0.47%
+677.00
+33.88%
Jun 30, 2025
Morgan Stanley & Co. LLC
28.00
0%
+28.00
--
Sep 30, 2025
Barrett & Company, Inc.
8.00
0%
--
--
Jun 30, 2025
Climaco (John Michael)
8.00
0%
--
--
May 09, 2025
BofA Global Research (US)
4.00
0%
+3.00
+300.00%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Nov 28, 2022
Merger
30→1
Mehr Anzeigen
